CPI

Eurosystem staff macroeconomic projections for the euro area, December 2023

Retrieved on: 
Wednesday, January 3, 2024

In doing so, we provide a rare application of the NGFS climate scenarios to economic assessment through the lens of the macroeconomic modelling frameworks underlying the scenario construction (e.g.

Key Points: 
  • In doing so, we provide a rare application of the NGFS climate scenarios to economic assessment through the lens of the macroeconomic modelling frameworks underlying the scenario construction (e.g.
  • Full recycling through government investment yields the strongest output multiplier, whereas recycling through household transfers or reduced income taxes yields the lowest multiplier.
  • During the transition, euro area macroeconomic variables respond very similarly if two-pillar or price level-targeting monetary policy rules are followed.

EQS-News: CPI PROPERTY GROUP – Completion of the Share Buy-back Offer

Retrieved on: 
Saturday, December 30, 2023

On 20 November 2023, CPI PROPERTY GROUP (“CPIPG” or the “Company”) announced the intention to purchase up to 105,000,000 shares under CPIPG’s share buy-back programme (the "Offer").

Key Points: 
  • On 20 November 2023, CPI PROPERTY GROUP (“CPIPG” or the “Company”) announced the intention to purchase up to 105,000,000 shares under CPIPG’s share buy-back programme (the "Offer").
  • On 30 November 2023 the Company announced that at the closing of the Offer period, shareholders of the Company presented a total of 85,327,468 shares for tender (the “Tendered Shares”).
  • The Company now announces the completion of the acquisition of 85,327,468 Tendered Shares for an aggregate price of EUR 79,525,200.18 (or EUR 0.932 per Tendered Share).
  • In addition, the Company’s indirect subsidiary, Pietroni, holds 67,000,000 Company shares (0.77% of the total shares outstanding).

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

Retrieved on: 
Thursday, December 28, 2023

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell’s Bria-IMT™ regimen.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell’s Bria-IMT™ regimen.
  • iORR is defined as the percentage of patients who achieve either a complete response (complete disappearance) or partial response (volume reduction of 30% or more) in intracranial tumors.
  • Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death.
  • BriaCell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT™ monotherapy and combination therapy with CPI studies and found remarkable clinical responses.

From The Highs to The Lows: CheapOair.ca Looks Ahead At What 2024 Holds For Canadian Travellers

Retrieved on: 
Tuesday, December 12, 2023

This year was not without its fair share of successes and issues, despite continuing inflation, fluctuating fuel costs, and global instability.

Key Points: 
  • This year was not without its fair share of successes and issues, despite continuing inflation, fluctuating fuel costs, and global instability.
  • While global inflation is expected to fall in 2024, CheapOair.ca anticipates that the new year will still see further surprises and challenges for travelers.
  • In its Consumer Price Index (CPI), the agency reported that the price of air transportation dropped 19.4% last month compared with October 2022.
  • While global inflation is set to fall in 2024, it will continue to impact hotel costs, according to the report.

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023

Retrieved on: 
Friday, December 8, 2023

This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.

Key Points: 
  • This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.
  • TILT’s approach uses oncolytic viruses to selectively replicate in and lyse cancer cells, while simultaneously stimulating immune responses towards the tumor.
  • The data announcement at ESMO-IO relates to 16 patients with checkpoint inhibitor (CPI) resistant progressive metastatic melanoma, who were treated with multiple intravenous and intratumoral injections of TILT-123 and a one- or two- time treatment with TILs.
  • The company has several trials currently underway, reflecting its commitment to pushing the boundaries of cancer treatment (NCT04217473, NCT05271318, NCT05222932).

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Retrieved on: 
Wednesday, December 6, 2023

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.

Key Points: 
  • 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).
  • The data is being revealed at the 2023 San Antonio Breast Cancer Symposium® held at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • In summary, the consistent topline survival and clinical benefits support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and support the ongoing pivotal study of our combination regimen in the treatment of advanced metastatic breast cancer.

Gentherm Announces Laura Kowalchik as New Independent Director

Retrieved on: 
Wednesday, December 6, 2023

Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer and distributor of engine drive systems and aftermarket services for automotive, heavy-duty, and industrial markets.

Key Points: 
  • Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer and distributor of engine drive systems and aftermarket services for automotive, heavy-duty, and industrial markets.
  • Before Dayco, she served as the Chief Financial Officer of Kenwal Steel Corp., a flat rolled steel service center primarily for the automotive industry.
  • “On behalf of the Board, I am happy to welcome Laura to Gentherm,” said Ronald Hundzinski, Chair of the Board of Gentherm.
  • She has a Bachelor of Science in Business Administration from the University of Richmond and a Master of Business Administration from Indiana University.

Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment

Retrieved on: 
Tuesday, December 5, 2023

It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.

Key Points: 
  • It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.
  • This may also explain why clonal neoantigen targeting immunotherapies like Gradalis’ Vigil have shown longer-term overall survival benefits in a randomized controlled trial of patients with solid tumors.
  • Clonal mutations expressed on the cancer surface provide a distinguishing difference between cancer cells and normal non-cancer cells.
  • Emerging research shows that targeting clonal mutations may be critical in achieving a durable clinical benefit,” stated John Nemunaitis, MD, Chief Scientific Officer of Gradalis and co-author of the paper.

Azrieli Group Reports Q3/2023 Results

Retrieved on: 
Monday, November 27, 2023

The increase was partially offset by non-inclusion of Compass’s results already in the current quarter.

Key Points: 
  • The increase was partially offset by non-inclusion of Compass’s results already in the current quarter.
  • TEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Danna Azrieli, Chairwoman of Azrieli Group, said: “The State of Israel is in the midst of a war, and Azrieli Group is entirely committed to the effort and to civil aid on all fronts.
  • We will continue acting on this commitment while maintaining financial strength and responsible conduct in these challenging times, which create both a complex business environment and opportunities.”
    Eyal Henkin, CEO of Azrieli Group, said: “As we mobilize and provide resources, Azrieli Group is closing another good quarter with continued growth in all parameters.
  • The sale of the Group’s minority holdings in Compass reflects a gross yield of x2.5 on the investment (in total, Azrieli Group invested in Compass approx.

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

Retrieved on: 
Tuesday, November 21, 2023

EDGEWOOD, N.Y., Nov. 21, 2023 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) announced that Embraer S.A. of Brazil (NYSE: ERJ) has placed several additional orders against a previously announced Long Term Agreement to manufacture engine inlet assemblies for the Embraer Phenom 300 business jets.

Key Points: 
  • EDGEWOOD, N.Y., Nov. 21, 2023 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) announced that Embraer S.A. of Brazil (NYSE: ERJ) has placed several additional orders against a previously announced Long Term Agreement to manufacture engine inlet assemblies for the Embraer Phenom 300 business jets.
  • These new orders will see deliveries continue into 2024.
  • “CPI Aero is proud to be part of the successful Phenom 300 program where we continue to demonstrate our capabilities in assembly & integration of complex, mixed-commodity Aerostructures.
  • During the last 10+ years, we have delivered over 1,600 Engine Inlet Assemblies and fully expect to continue serving this important customer beyond 2024,” stated Dorith Hakim, CPI Aero’s CEO & President.